IXICO is presenting its Assessa® PML digital healthcare platform at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress on 16 September 2016. Assessa® PML is based on IXICO’s existing Assessa® technology, and has been designed as part of a collaboration including IXICO, clinical experts in specialist centres in The Netherlands, Germany, Switzerland, France, Italy, Spain and UK, with financial support from Biogen Inc., (NASDAQ: BIIB) through a collaboration agreement announced in October 2015.
Progressive Multifocal Leukoencephalopathy (PML) is a potentially fatal side effect of certain drug treatments for Multiple Sclerosis (MS). Assessa® PML is designed to be used alongside such drugs to support the early detection of PML. It could therefore improve uptake of effective treatments by providing improved management of PML risks.